Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn:
“The FDA has granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive mCRPC after ARPI, based on promising phase 1/2a SECuRE trial data.
- No dose-limiting toxicities in 15 patients.
- 73% had PSA reductions, with 45% showing >50% decline after a single dose.
- Mild side effects, most commonly dry mouth (33%).
This could be a game-changer in PSMA-targeted radiotherapy, offering an alternative to 177Lu-based treatments.
Looking forward to further developments!”